



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/SG/2024-25/122

November 10, 2024

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code - 532523</b>	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol - Biocon</b>
--	---

Dear Sir/Madam,

**Subject: Notification to Stock Exchanges**

Please find enclosed the company statement titled “**USFDA Classifies Biocon Biologics’ Biocon Park Site in Bengaluru, India as Voluntary Action Initiated (VAI)**”.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

\_\_\_\_\_  
**Mayank Verma**  
**Company Secretary & Compliance Officer**  
**Membership No: ACS 18776**

Encl: as above

## NOTIFICATION TO STOCK EXCHANGE

### COMPANY STATEMENT

#### **USFDA Classifies Biocon Biologics' Biocon Park Site in Bengaluru, India as Voluntary Action Initiated (VAI)**

***Bengaluru, Karnataka, India, November 10, 2024***

“The U.S. Food and Drug Administration (FDA) has classified Biocon Biologics’ facilities at Biocon Park, Bengaluru, India, as Voluntary Action Indicated (VAI).

“This relates to the combined cGMP inspection and Pre-Licensing Inspection (PLI) conducted by the agency between July 15 – 26, 2024. The inspection scope had included six (6) separate Biologics manufacturing units comprising of four (4) Drug Substance and two (2) Drug Product manufacturing plants as well as five (5) Analytical Quality Control Laboratories, four (4) Microbiology Laboratories, and two (2) Warehouses.

“Biocon Biologics remains committed to global standards of Quality and Compliance.”

– *Company Spokesperson*